In an effort to develop and commercialize central nervous system disorder therapies, such as Alzheimer’s disease and schizophrenia, Vanderbilt University’s Warren Center for Neuroscience Drug Discovery (VCNDD) entered into an exclusive worldwide licensing and...
Neurodegenerative Disease
Category
Canadian National Parkinson’s Registry Seeking Participants to Help Advance Treatments
Parkinson Canada now invites individuals living with Parkinson’s disease to join the Canadian Open Parkinson Network (C-OPN), a solution to improve lives for those living with Parkinson’s and ultimately to help discovery a cure. Phase One of the Registry & Biobank...
Cognition Therapeutics Wins $75.8m Prestigious ACTC Grant for Alzheimer’s Disease Clinical Trial
Cognition Therapeutics, Inc. secured a $75.8 million, five-year grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) to support a 540-patient Phase II clinical trial of CT1812 in individuals with early Alzheimer’s disease. The...
Vanderbilt University Secures $20m from William K. Warren Foundation to Further Treatments for Brain Disorders
Vanderbilt University received $20 million from the William K Warren Foundation located in Tulsa, Oklahoma to establish the Warren Center for Neuroscience Drug Discovery. This adds to the Center for Neuroscience Drug Discovery, led by co-directors Craig Lindsley and...
First Alzheimer’s Drug Approved in China Comes to U.S. Clinical Trials as FDA Approves China’s Green Valley Pharma’s IND
Toward the end of last year, TrialSite News introduced the first approved Alzheimer’s disease (AD) drug approved in years; Chinese regulators approved the drug Oligomannate (GV-971) made by Green Valley Pharmaceuticals. They made good on their promise to hit America...
Young Investigators Profile: Virginia Tech’s Christopher Liao Pursues a Better Understanding of Alzheimer’s Disease
Virginia Tech’s Christopher Liao, a four-year Carilion School of Medicine student, developed novel insight into Alzheimer’s disease as part of his graduate research project. Specifically looking for how the neurodegenerative disease impacted blood vessels in the brain...
University of Helsinki Researchers Find a Molecule (BT13) that has Therapeutic Potential Against Parkinson’s Disease
University of Helsinki researchers made a breakthrough in their discovery that a molecule known as BT13 has the potential as a therapeutic for Parkinson’s disease. In preclinical research studies including in vitro and in vivo studies in mouse models, the Finnish team...
Dr. Reisa Sperling & Brigham and Women’s Hospital—the Investigative Race to Find Treatments for Alzheimer’s Disease
Dr. Reisa Sperling with Brigham and Women’s Hospital is one of the nation’s top experts when it comes to Alzheimer’s disease. And it is deeply personal for her as the neurodegenerative condition hit her grandfather while she was in medical school and three years ago,...
Temple University Preclinical Investigators Reveal Pharmacological Chaperone Therapy May Prevent Alzheimer’s Disease in Mice
Preclinical researchers at Temple University’s Lewis Katz School of Medicine continue the battle against Alzheimer’s disease—a continuous effort to study novel approaches and experimental therapies that hopefully will some day develop a way to stop this insidious and...
Global Alzheimer’s Disease Study Comes to Rhode Island’s Alzheimer’s Disease and Memory Disorders Center
Rhode Island Hospital’s Alzheimer’s Disease and Memory Disorders Center, led by Jonathan Drake, associate director, recently was in the news for their participation in the new Clarity AD study looking at a new experimental infused treatment for Alzheimer’s disease...
Dartmouth-Hitchcock & UMass Boston Receive $1.2m to Develop AI-enabled Voice Detection via Alexa & Others
Researchers from Dartmouth-Hitchcock and the University of Massachusetts Boston have received a four-year, $1.2 million grant from the National Institute on Aging in an exciting effort to use voice-assistant devices like Amazon’s Alexa to detect signs of memory...
McGill University Led Study Develops Breakthrough AI to Predict Progression of Neurodegenerative Disease
Brain researchers from Montreal Neurological Institute, the Hospital of McGill University, and the Ludmer Centre for Neuroinformatics and Mental Health recently concluded a study revealing that artificial intelligence (AI) algorithms reveal the potential to predict...
Michigan State University a Hub of Alzheimer’s Research in Western Michigan with Influence Beyond
A Michigan State University (MSU) is researching a cure for Alzheimer’s disease. Located at the MSU Grand Rapids Research Center, the Alzheimer’s Alliance conducts a series of clinical trials, connecting people who have the disease with researchers trying to stop it....
University College London-Led Study Reveals Ambroxol Evidences Promise as Parkinson’s Disease Drug
A team led by University College London Institute of Neurology discovered ambroxol therapy could be used as a neuroprotective compound to treat patients with Parkinson’s disease both with and without glucocerebrosidase (GBA1) gene mutations. This study was sponsored...
Morton Plant Hospital in Clearwater Joins Clinical Trial to Investigate New Way to Detect Alzheimer’s Disease
Morton Plant Hospital in Clearwater, Florida in the Tampa Bay region has signed up to participate in a clinical trial evaluating novel Alzheimer’s disease detection method. The goal is to drastically impact the lives of thousands of people and family members dealing...
University of Aberdeen Participates in Huntington’s Disease Study and Patient’s Focuses on the Good
The University of Aberdeen, led by Zosia Miedzybrodzka, cares for Huntington’s disease (HD) patients, such as Sandy Patience of Scotland, as the 801 patient global study known as Generation-HD1 unfolds. Patience inherited this condition and declared the clinical...
Cutting-Edge Clinical Trial to Test Retinal Screening as Process for Early Detection of Alzheimer’s Disease
The University of Rhode Island, Florida’s BayCare Health System, and the Memory and Aging Program at Butler Hospital are launching a clinical trial with profound implications: what if a standard eye examination inclusive of a retinal scan could detect biomarkers...
The Dementia Treatment Mission Moves into a New Decade in the UK and Beyond
Unsuccessful drug trials, insufficient funding, and patients too ill to participate in trials spell trouble for the war against dementia. The degradation, struggle and cost in the UK (as well as America and elsewhere) will rise exponentially. The Daily...
The New Chinese Alzheimer’s Drug (GV-971) Making its Way to Global Trials: Material Science or Marketing?
Is the world ready for GV-971(Oligomannate)? Because the first new approved Alzheimer’s drug in many years is coming to a clinical trial near you. Conditionally approved by China’s regulators, many in the West are skeptical. However, industry sponsor Green Valley...
UCSF-Led Study Reveals Tau Superior to Amyloid in Predicting Impacts on Brain Tissue Involving Alzheimer’s Disease
Research from the UC San Francisco (UCSF) Memory and Aging Center in collaboration with UC Berkeley and Lawrence Livermore Laboratory reveals that brain imaging of pathological tau-protein (“tangles”) reliably predicts the location of future brain atrophy in...